Construction of a bivalent vaccine against anthrax and smallpox using the attenuated vaccinia virus KVAC103

BMC Microbiology

article

Park, Deok Bum¹  Rhie, Gi-eun¹  Ahn, Bo-Eun¹  Son, Hosun³  Lee, Young-Ran¹  Kim, Yu-Ri¹  Jo, Su Kyoung¹  Chun, Jeong-Hoon¹  Yu, Jae-Yon¹  Choi, Myung-Min¹ 

[1] Division of High-risk Pathogens;Present address: Forensic DNA Division, Gwangju Institute, National Forensic Service;Division of Vaccine Research, Korea National Institute of Health, Korea Centers for Disease Control and Prevention;Present address: Convergence Bioceramic Materials Center, Korea Institute of Ceramic Engineering and Technology

关键词: Anthrax;    Smallpox;    Vaccinia virus;    IL-15;    Cholera toxin;   

DOI  :  10.1186/s12866-021-02121-5

学科分类：放射科、核医学、医学影像

来源: BioMed Central

【 摘 要 】

Anthrax and smallpox are high-risk infectious diseases, and considered as potential agents for bioterrorism. To develop an effective countermeasure for these diseases, we constructed a bivalent vaccine against both anthrax and smallpox by integrating a gene encoding protective antigen (PA) of Bacillus anthracis to the genome of the attenuated vaccinia virus strain, KVAC103. Immunization with this bivalent vaccine induced antibodies against both PA and vaccinia virus in a mouse model. We also observed that the efficacy of this vaccine can be enhanced by combined immunization with immunoadjuvant-expressing KVAC103. Mouse groups co-immunized with PA-expressing KVAC103 and either interleukin-15 (IL-15) or cholera toxin subunit A (CTA1)-expressing KVAC103 showed increased anti-PA IgG titer and survival rate against B. anthracis spore challenge compared to the group immunized with PA-expressing KVAC103 alone. We demonstrated that the attenuated smallpox vaccine KVAC103 is an available platform for a multivalent vaccine and co-immunization of immunoadjuvants can improve vaccine performance.

【 授权许可】

CC BY|CC0